ERS statement on benign pleural effusions in adults
Sundaralingam A., Grabczak EM., Burra P., Costa MI., George V., Harriss E., Jankowska EA., Janssen JP., Karpathiou G., Laursen CB., Maceviciute K., Maskell N., Mei F., Nagavci B., Panou V., Pinelli V., Porcel JM., Ricciardi S., Shojaee S., Welch H., Zanetto A., Udayaraj UP., Cardillo G., Rahman NM.
The incidence of non-malignant pleural effusions far outweighs that of malignant pleural effusions and is estimated to be at least 3-fold higher. These so-called benign effusions do not follow a “benign course” in many cases, with mortality rates matching and sometimes exceeding those of malignant pleural effusions. In addition to the impact on patients, healthcare systems are also significantly affected, with recent US epidemiological data demonstrating that 75% of resource allocation for pleural effusion management is spent on non-malignant pleural effusions (excluding empyema). Despite this significant burden of disease, and by existing at the junction of multiple medical specialties, reflecting a heterogenous constellation of medical conditions, non-malignant pleural effusions are rarely the focus of research or the subject of management guidelines. With this European Respiratory Society Task Force, we assembled a multispecialty collaborative across 11 countries and three continents to provide a statement based on systematic searches of the medical literature to highlight evidence in the management of the following clinical areas: a diagnostic approach to transudative effusions, heart failure, hepatic hydrothorax, end-stage renal failure, benign asbestos-related pleural effusion, post-surgical effusion and nonspecific pleuritis.